Astonea Labs Ltd. (ASTONEALAB) 52 Week High Streak: Second Straight Session Near One-Year Peak
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: News
Astonea Labs Ltd. has now traded within 2% of its 52-week high for its second straight session, and the latest Univest data confirms the pattern without establishing a company-specific catalyst. ASTONEALAB last traded at Rs 413, up Rs 3 or 0.73% from the previous close, while the streak shows a cumulative move of -0.12% across the two sessions. The stock also touched a high of Rs 413 in the current move.
The previous close was Rs 410, and the stock opened at Rs 413 before touching its intraday low of Rs 413 as well. That leaves the move tightly contained within a flat range on the day. With market capitalisation at Rs 434.63 crore, the repeated near-high pattern matters more than a single-day print because it shows the stock is spending more than one session near its yearly peak rather than briefly visiting it once.
Astonea Labs Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 413 |
| Previous Close | Rs 410 |
| Today's Move | +Rs 3 (+0.73%) |
| Open | Rs 413 |
| High | Rs 413 |
| Low | Rs 413 |
| Market Capitalisation | Rs 434.63 crore |
Astonea Labs Ltd. (ASTONEALAB) traded at Rs 413 versus the previous close of Rs 410, a rise of 0.73%. The stock opened at Rs 413, reached a high of Rs 413 and touched a low of Rs 413.
Astonea Labs Ltd. Share Price Today shows ASTONEALAB trading at Rs 413, above the previous close of Rs 410 by Rs 3 or 0.73%. The stock opened at Rs 413, moved to a high of Rs 413 and a low of Rs 413, so the price action stayed compressed through the day’s range. For readers tracking the Astonea Labs Ltd. stock price, the point to note is not a large intraday swing but the fact that the share price has remained close to its yearly high across more than one session.
The company’s market capitalisation stands at Rs 434.63 crore. That places the move in the context of a small-cap-sized company by value, but the chart read here is narrower: the stock is still trading near its 52-week high and the latest Univest data shows a repeat of that pattern. Because the move has been repeated rather than isolated, the Astonea Labs Ltd. share price today is being watched as part of an extended high streak rather than a one-off jump.
What the Repeated 52-Week Highs Show
The repeated near-high pattern suggests persistence rather than a single sharp move, and that is the key difference between a one-session spike and a multi-session 52-week high streak. For Astonea Labs Ltd., the latest reading confirms that ASTONEALAB has stayed within 2% of its one-year peak for a second straight session. The cumulative change across the streak is still slightly negative at -0.12%, which means the stock has held near its peak zone without materially extending away from it.
That matters because repeated highs often draw attention to the same stock price zone over several sessions. In this case, however, the latest Univest data does not establish why the move has persisted. There is no company-specific catalyst confirmed here, so the pattern should be read as a market fact rather than a story about a fresh trigger. For investors, the useful question is whether the share price can keep holding near the yearly high while fundamentals and relative valuation stay in view.
Astonea Labs Ltd. (ASTONEALAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 434.63 crore |
| P/E Ratio | 95.44x |
| P/B Ratio | 7.54x |
| ROE | 11.95% |
| ROCE | 10.51% |
| EPS | Rs 4.3 |
| Book Value Per Share | Rs 54.35 |
| Dividend Yield | 0% |
Astonea Labs Ltd. (ASTONEALAB) fundamental metrics show P/E 95.44x, P/B 7.54x, ROE 11.95%, ROCE 10.51%. These figures provide context only and are not a buy or sell signal.
Astonea Labs Ltd. has a market capitalisation of Rs 434.63 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 95.44x, P/B at 7.54x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.95% and ROCE of 10.51%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 4.3, book value per share of Rs 54.35, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.53x, median ROE of 10.98%, median ROCE of 13.1%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 95.44x |
| Benchmark Median P/E | 26.53x |
| Benchmark Average P/E | 50.75x |
| Benchmark P/E Range | 0x to 1,378.1x |
| Company P/B Ratio | 7.54x |
| Benchmark Median P/B | 2.78x |
| Company ROE | 11.95% |
| Benchmark Median ROE | 10.98% |
| Company ROCE | 10.51% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 434.63 crore |
| Benchmark Median Market Cap | Rs 789.58 crore |
Astonea Labs Ltd. (ASTONEALAB) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astonea Labs Ltd. (ASTONEALAB) has a P/E ratio of 95.44x, which is above the benchmark median of 26.53x, a difference of +259.74%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astonea Labs Ltd. (ASTONEALAB) has a ROE of 11.95%, which is above the benchmark median of 10.98%, a difference of +8.83%. Astonea Labs Ltd. (ASTONEALAB) has a ROCE of 10.51%, which is below the benchmark median of 13.1%, a difference of -19.77%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Albert David Ltd. | ALBERTDAVD | 430.09 | 14.96 | 1.02 | -0.38 | 0.83 |
| Medicamen Biotech Ltd. | MEDICAMEQ | 413.24 | 35.48 | 1.36 | 4.23 | 6 |
| Jenburkt Pharmaceuticals Ltd. | JENBURPH | 409.02 | 12.44 | 2 | 18.84 | 25.34 |
| Trident Lifeline Ltd. | TLL | 479.36 | 25.11 | 4.43 | 24.83 | 22.71 |
| SMS Lifesciences India Ltd. | HALEOSLABS | 490.82 | 38.44 | 2.27 | 8.68 | 10.53 |
Astonea Labs Ltd. (ASTONEALAB) has a P/E ratio of 95.44x compared with the displayed peer median of 25.11x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.95% compares with a peer median of 8.68% across the companies shown in the table. ROCE stood at 10.51% versus the displayed peer median of 10.53%, providing a capital-efficiency comparison. Astonea Labs Ltd. (ASTONEALAB) has a market capitalisation of Rs 434.63 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Astonea Labs Ltd.
- Astonea Labs Ltd. has traded within 2% of its 52-week high for a second straight session.
- The latest Univest figures show a cumulative streak move of -0.12% across the two sessions.
- ASTONEALAB last traded at Rs 413, with the day’s range staying at Rs 413 to Rs 413.
- The company’s P/E ratio of 95.44 is well above the Healthcare industry median of 26.53.
- Market capitalisation stands at Rs 434.63 crore, keeping the stock in focus for Stock News and Market Update readers.
About Astonea Labs Ltd.
Astonea Labs Ltd. is listed on NSE and BSE under the symbol ASTONEALAB. The company belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. In the latest market view, the stock is being followed for its near one-year high pattern, valuation premium and small-cap-sized market value. For readers tracking Astonea Labs Ltd. Share Price Today, the main context is the combination of repeated near-high trading and a valuation that sits above the industry median.
The company’s latest ratios show EPS of Rs 4.3, book value of Rs 54.35, ROE of 11.95% and ROCE of 10.51%. That set of numbers gives a basic operating and valuation frame around the Astonea Labs Ltd. stock performance, especially when compared with pharmaceutical peers in the same industry group.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does Astonea Labs Ltd. 52 Week High Streak mean?
Ans. It means Astonea Labs Ltd. has traded within 2% of its 52-week high for consecutive sessions. In this case, the streak has reached a second straight session, which keeps ASTONEALAB in the near-year-high zone.
How many sessions has Astonea Labs Ltd. traded near its 52-week high?
Ans. The stock has traded within 2% of its 52-week high for two consecutive sessions. The latest Univest data confirms the repeated pattern and shows that the stock remains close to its one-year peak.
What is the current Astonea Labs Ltd. share price today?
Ans. ASTONEALAB last traded at Rs 413. The stock was up Rs 3, or 0.73%, versus the previous close of Rs 410, with the day’s open, high and low all at Rs 413.
Is there a confirmed catalyst behind the repeated near-high move?
Ans. No company-specific catalyst is confirmed by the latest Univest data. The figures show the price pattern, but they do not identify a fresh event or announcement as the reason for the repeated move.
How expensive is Astonea Labs Ltd. compared with its sector?
Ans. The stock trades at a P/E of 95.44 and a P/B of 7.54, both above the Healthcare industry medians of 26.53 and 2.78. That places the valuation above the broader benchmark in the latest snapshot.
What do the return ratios show for Astonea Labs Ltd.?
Ans. ROE stands at 11.95% and ROCE at 10.51%. These figures are not uniform across the sector comparison, but they provide a useful operating backdrop for the stock’s current valuation.
How does Astonea Labs Ltd. compare with peers on valuation?
Ans. Its P/E is higher than several peers such as Albert David Ltd., Jenburkt Pharmaceuticals Ltd. and Wanbury Ltd., while also above Medicamen Biotech Ltd. and SMS Lifesciences India Ltd. That makes the stock one of the pricier names in the peer set.
What should investors monitor next in Astonea Labs Ltd.?
Ans. Investors can watch whether the stock continues to trade near its yearly high, whether valuation remains supported by fundamentals, and how the share price behaves relative to the peer group. The repeated near-high pattern is the key market signal here.
Track Astonea Labs Ltd. (ASTONEALAB) Share Price on Univest
Use Astonea Labs Ltd. (ASTONEALAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.